Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL497409 | 0.99 | NOS3 (0.37) | NOS3NOS1NOS2CYP19A1 | |
| SCHEMBL497384 | 0.79 | NOS3 (0.44) | NOS3NOS1NOS2CYP19A1 | |
| SCHEMBL497387 | 0.79 | NOS3 (0.38) | NOS3NOS1NOS2CYP19A1 | |
| Hydrochloric Acid SCHEMBL497411 | 0.78 | NOS3 (0.43) | NOS3NOS1NOS2CYP19A1 | |
| Hydrochloric Acid SCHEMBL497458 | 0.78 | NOS3 (0.37) | NOS3NOS1NOS2CYP19A1 | |
| SCHEMBL4657444 | 0.76 | CYP19A1 (0.32) | CYP19A1 | |
| Hydrochloric Acid SCHEMBL11009063 | 0.63 | NOS3 (0.39) | NOS3NOS1NOS2 | |
| SCHEMBL13588438 | 0.63 | NOS3 (0.35) | NOS3NOS1NOS2 | |
| SCHEMBL700847 | 0.63 | CYP19A1 (0.32) | CYP19A1 | |
| Hydrochloric Acid SCHEMBL702555 | 0.62 | CYP19A1 (0.31) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1999112-B1 | SUBSTITUTED 2-AMINO-4-PHENYL-DIHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM | SANOFI SA (FR) | 2015-04-22 | — | — | EP | claimed |
| US-8106204-B2 | Substituted 2-amino-4-phenyldihydroquinolines, processes for their preparation, pharmaceutical compositions and methods for their use | SANOFI-AVENTIS (FR) | 2012-01-31 | — | — | US | claimed |
| US-20090118329-A1 | Novel Substituted 2-Amino-4-Phenyldihydroquinolines, Processes for their Preparation, Pharmaceutical Compositions and Methods for Their Use | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | US | claimed |
| EP-1999112-A2 | SUBSTITUTED 2-AMINO-4-PHENYL-D HYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM | Sanofi-Aventis (FR) | 2008-12-10 | — | — | EP | claimed |
| WO-2007107246-A2 | SUBSTITUTED 2-AMINO-4-PHENYL-DιHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM | SANOFI-AVENTIS (DE) | 2007-09-27 | — | — | WO | claimed |
| EP-1999112-B1 | SUBSTITUTED 2-AMINO-4-PHENYL-DIHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM | SANOFI SA (FR) | 2015-04-22 | — | — | EP | disclosed |
| EP-1999112-B1 | SUBSTITUTED 2-AMINO-4-PHENYL-DIHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM | SANOFI SA (FR) | 2015-04-22 | — | — | EP | disclosed |
| US-8106204-B2 | Substituted 2-amino-4-phenyldihydroquinolines, processes for their preparation, pharmaceutical compositions and methods for their use | SANOFI-AVENTIS (FR) | 2012-01-31 | — | — | US | disclosed |
| US-8106204-B2 | Substituted 2-amino-4-phenyldihydroquinolines, processes for their preparation, pharmaceutical compositions and methods for their use | SANOFI-AVENTIS (FR) | 2012-01-31 | — | — | US | disclosed |
| US-8106204-B2 | Substituted 2-amino-4-phenyldihydroquinolines, processes for their preparation, pharmaceutical compositions and methods for their use | SANOFI-AVENTIS (FR) | 2012-01-31 | — | — | US | disclosed |
| US-20090118329-A1 | Novel Substituted 2-Amino-4-Phenyldihydroquinolines, Processes for their Preparation, Pharmaceutical Compositions and Methods for Their Use | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | US | disclosed |
| US-20090118329-A1 | Novel Substituted 2-Amino-4-Phenyldihydroquinolines, Processes for their Preparation, Pharmaceutical Compositions and Methods for Their Use | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | US | disclosed |
| US-20090118329-A1 | Novel Substituted 2-Amino-4-Phenyldihydroquinolines, Processes for their Preparation, Pharmaceutical Compositions and Methods for Their Use | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | US | disclosed |
| EP-1999112-A2 | SUBSTITUTED 2-AMINO-4-PHENYL-D HYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM | Sanofi-Aventis (FR) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107246-A2 | SUBSTITUTED 2-AMINO-4-PHENYL-DιHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM | SANOFI-AVENTIS (DE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107246-A2 | SUBSTITUTED 2-AMINO-4-PHENYL-DιHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM | SANOFI-AVENTIS (DE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118329-A1 | Novel Substituted 2-Amino-4-Phenyldihydroquinolines, Processes for their Preparation, Pharmaceutical Compositions and Methods for Their Use | NHERF1, SLC10A1, SLC9A3 | NOS3 588/4885NOS1 1649/4885NOS2 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.